Abstract：
To evaluate the effects of antimicrobial peptides (AMPs) on Stage III Grade B periodontitis.
This trial abided by the principle of consistency test, approved by ethics committee and registered in clinical trials. All qualified 51 patients with Stage III Grade B periodontitis were randomly divided into three groups: SRP group, SRP with minocycline hydrochloride (Mino group) as Control groups, and SRP with AMPs (AMP group) as the Test group. Clinical examinations and subgingival plaques were monitored at baseline and at 7 and 90 days after treatment in the SRP, SRP with AMP and Mino groups.
The AMP group (Test group) had a reduced PD (Periodontal probing depth) and an attachment gain significantly higher than SRP and Mino groups (Control groups) at day 90. The abundance of periodontal pathogens was decreased in the AMP group at 7 and 90 days compared with the SRP group and Mino group. Only the AMP group showed an increase the abundance of periodontal probiotics including Capnocytophaga, Gemella, and Lactobacillus at 7 and 90 days.
This study shows that AMPs as an adjunct to SRP promote additional clinical and microbiological benefits in the treatment of Stage III Grade B periodontitis.
This trial abided by the principle of consistency test, approved by ethics committee and registered in clinical trials. All qualified 51 patients with Stage III Grade B periodontitis were randomly divided into three groups: SRP group, SRP with minocycline hydrochloride (Mino group) as Control groups, and SRP with AMPs (AMP group) as the Test group. Clinical examinations and subgingival plaques were monitored at baseline and at 7 and 90 days after treatment in the SRP, SRP with AMP and Mino groups.
The AMP group (Test group) had a reduced PD (Periodontal probing depth) and an attachment gain significantly higher than SRP and Mino groups (Control groups) at day 90. The abundance of periodontal pathogens was decreased in the AMP group at 7 and 90 days compared with the SRP group and Mino group. Only the AMP group showed an increase the abundance of periodontal probiotics including Capnocytophaga, Gemella, and Lactobacillus at 7 and 90 days.
This study shows that AMPs as an adjunct to SRP promote additional clinical and microbiological benefits in the treatment of Stage III Grade B periodontitis.
摘要：
背景：评估抗菌肽（AMPs）对III期B级牙周炎的影响。
方法：本试验遵循一致性检验的原则，经伦理委员会批准并在临床试验中注册。所有符合条件的51例Ⅲ期B级牙周炎患者随机分为3组:SRP组,SRP以盐酸米诺四环素（米诺）为对照组，以AMP(AMP组)为试验组的SRP。在基线和SRP治疗后第7天和第90天监测临床检查和龈下斑块，带AMP和Mino组的SRP。
结果：在第90天，AMP组（测试组）的PD（牙周探查深度）减少，并且附着增益显着高于SRP和Mino组（对照组）。与SRP组和Mino组相比，AMP组在7天和90天时牙周病原体的丰度降低。只有AMP组显示牙周益生菌的丰度增加，包括Capnocytophaga，Gemella,和乳酸菌在7天和90天。
结论：这项研究表明，作为SRP的辅助药物，AMPs在治疗III期B级牙周炎中具有额外的临床和微生物学益处。
方法：本试验遵循一致性检验的原则，经伦理委员会批准并在临床试验中注册。所有符合条件的51例Ⅲ期B级牙周炎患者随机分为3组:SRP组,SRP以盐酸米诺四环素（米诺）为对照组，以AMP(AMP组)为试验组的SRP。在基线和SRP治疗后第7天和第90天监测临床检查和龈下斑块，带AMP和Mino组的SRP。
结果：在第90天，AMP组（测试组）的PD（牙周探查深度）减少，并且附着增益显着高于SRP和Mino组（对照组）。与SRP组和Mino组相比，AMP组在7天和90天时牙周病原体的丰度降低。只有AMP组显示牙周益生菌的丰度增加，包括Capnocytophaga，Gemella,和乳酸菌在7天和90天。
结论：这项研究表明，作为SRP的辅助药物，AMPs在治疗III期B级牙周炎中具有额外的临床和微生物学益处。
